SARS-CoV-2 B.1.351 spike exhibits the superior immunogenicity among multiple variants
Description
Figure S1. Heat map of IgG binding antibodies induced by Ad5-B.1.1.7, Ad5-B.1.351, Ad5-P.1, Ad5-B.1.429 and Ad5-WT in mice. BALB/c mice (n = 10 per group) received a single intramuscular immunization with Ad5-B.1.1.7, Ad5-B.1.351, Ad5-P.1, Ad5-B.1.429, Ad5-WT or Ad5-null at day 0. Sera were collected at 4 weeks after immunization, and IgG binding antibodies against spike, RBD, NTD of B.1.1.7, P.1.351, P.1 variants and the wild-type strain were detected using ELISA method. The data in the Ad5-null control group were not shown because all of them were sero-negative. Figure S2. Heat map of pseudovirus neutralizing antibodies induced by Ad5-B.1.1.7, Ad5-B.1.351, Ad5-P.1, Ad5-B.1.429 and Ad5-WT in mice. BALB/c mice (n = 10 per group) received a single intramuscular immunization with Ad5-B.1.1.7, Ad5-B.1.351, Ad5-P.1, Ad5-B.1.429, Ad5-WT or Ad5-null at day 0. Sera were collected at 4 weeks after immunization. Neutralization assays were performed using HIV backbone-derived pseudovirus bearing spikes of the wild-type strain and B.1.1.7, B.1.351, P.1, B.1.429 and B.1.617 variants using microneutralization assay based on luciferase reporter gene. The data in the Ad5-null control group were not shown because all of them were sero-negative. The PNAb GMT was standardized and transfromed to ratio compared to the highest GMT value of the vaccine group in each pseudovirus NAb test. Table S1. IgG GMT against spike, RBD and NTD of variants and wild-type strain induced by Ad5-B.1.1.7, Ad5-B.1.351, Ad5-P.1, Ad5-B.1.429, Ad5-WT or Ad5-null. Table S2. NAb GMT against HIV-derived pseudovirus bearing spikes of variants and wild-type strain induced by Ad5-B.1.1.7, Ad5-B.1.351, Ad5-P.1, Ad5-B.1.429, Ad5-WT or Ad5-null.